首页> 外文期刊>Breast Cancer Research and Treatment >The prognostic value of MARCKS-like 1 in lymph node-negative breast cancer
【24h】

The prognostic value of MARCKS-like 1 in lymph node-negative breast cancer

机译:MARCKS-like 1在淋巴结阴性乳腺癌中的预后价值

获取原文
获取原文并翻译 | 示例
           

摘要

There is a need for new biomarkers to more correctly identify node-negative breast cancer patients with a good or bad prognosis. Myristoylated alanine-rich C kinase substrate like-1 (MARCKSL1) is a membrane-bound protein that is associated with cell spreading, integrin activation and exocytosis. Three hundred and five operable T1,2N0M0 lymph node-negative breast cancer patients (median follow-up time 121 months, range 10–178 months) were evaluated for MARCKSL1 expression by immunohistochemistry and quantitative real-time PCR. The results were compared with classical prognosticators (age, tumor diameter, grade, estrogen receptor, and proliferation), using single (Kaplan–Meier) and multivariate survival analysis (Cox model). Forty-seven patients (15 %) developed distant metastases. With single and multivariate analysis of all features, MARCKSL1 protein expression was the strongest prognosticator (P < 0.001, HR = 5.1, 95 % CI = 2.7–9.8). Patients with high MARCKSL1 expression (n = 23) showed a 44 % survival versus 88 % in patients with low expression at 15-year follow-up. mRNA expression of MARCKSL1 in formalin fixed paraffin-embedded tissue was also prognostic (P = 0.002, HR = 3.6, 95 % CI = 1.5–8.3). However, the prognostic effect of high and low was opposite from the protein expression, i.e., low expression (relative expression ≤ 0.0264, n = 76) showed a 79 % survival versus 92 % in those with high expression of MARCKSL1 mRNA. Multivariate analysis of all features with distant metastases free survival as the end-point showed that the combination of MARCKSL1 protein and phosphohistone H3 (PPH3) has the strongest independent prognostic value. Patients with high expression (≥13) of PPH3 and high MARCKSL1 protein had 45 % survival versus 78 % survival for patients with low MARCKSL1 protein expression and high expression (≥13) of PPH3. In conclusion, MARCKSL1 has strong prognostic value in lymph node-negative breast cancer patients, especially in those with high proliferation.
机译:需要新的生物标记物以更正确地鉴定预后良好或不良的淋巴结阴性乳腺癌患者。富含肉豆蔻酰化的富含丙氨酸的C激酶底物样1(MARCKSL1)是一种膜结合蛋白,与细胞扩散,整合素激活和胞吐作用有关。 305例可手术的T 1,2 N 0 M 0 淋巴结阴性乳腺癌患者(中位随访时间为121个月,范围10–178个月)通过免疫组织化学和定量实时PCR评估了MARCKSL1的表达。使用单次(Kaplan–Meier)和多因素生存分析(Cox模型),将结果与经典预后(年龄,肿瘤直径,等级,雌激素受体和增殖)进行了比较。四十七名患者(15%)发生远处转移。通过所有特征的单变量和多变量分析,MARCKSL1蛋白表达是最强的预后因子(P <0.001,HR = 5.1,95%CI = 2.7-9.8)。在15年的随访中,MARCKSL1高表达的患者(n = 23)显示出44%的存活率,而低表达的患者则为88%。在福尔马林固定石蜡包埋的组织中,MARCKSL1的mRNA表达也具有预后性(P = 0.002,HR = 3.6,95%CI = 1.5-8.3)。但是,高和低的预后效果与蛋白质表达相反,即低表达(相对表达≤0.0264,n = 76)显示79%的存活率,而高表达MARCKSL1 mRNA的则为92%。对所有以远处转移为生存终点的特征进行多变量分析表明,MARCKSL1蛋白和磷酸化组蛋白H3(PPH3)的组合具有最强的独立预后价值。 PPH3高表达(≥13)和MARCKSL1蛋白高的患者生存率为45%,而MARCKSL1蛋白低表达和PPH3高表达(≥13)的患者生存率为78%。总之,MARCKSL1在淋巴结阴性乳腺癌患者中,尤其是在那些高增殖性乳腺癌患者中,具有很强的预后价值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号